Please login to the form below

Not currently logged in


This page shows the latest Nektar news and features for those working in and with pharma, biotech and healthcare.

BMS presses go on Nektar combo pivotal trials, despite data debate

BMS presses go on Nektar combo pivotal trials, despite data debate

Nektar and BMS also reported initial stage 1 data in urothelial cancer which revealed an ORR of 60%. ... to kick in, assert BMS and Nektar, although they struggled to get the message across amongst a storm of speculation on Twitter about the reasons

Latest news

More from news
Approximately 7 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    A clinical co-operation between Bristol-Myers Squibb and Nektar Therapeutics was closed under which Opdivo [nivolumab] will be evaluated in combination with Nektar's NKTR-214 in phase I/II

  • Deal Watch June 2016 Deal Watch June 2016

    acquisition company. 105. Nektar Therapeutics/ Daiichi Sankyo Europe. Onzeald (etirinotecan pegol), long-acting topoisomerase I inhibitor for metastatic breast cancer (phase III). ‡‡

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
CAN advertising

Brief us and you’ll soon see we really CAN do it all. We’re different to other agencies. You’ll get expert...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...